12 completed, 5 recruiting, 2 active not recruiting, 2 suspended. 24 Phase 2, 6 Phase 3.
Follow pretomanid: new trials by email Literature Review of pretomanid trials Research Report on pretomanid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Combinations of Novel Promising Drugs for Pulmonary Tuberculosis TBAJ-587 50 mg, Pretomanid 200mg, Linezolid 600Mg Tab - Tuberculosis, Pulmonary | Phase 2 | Not yet recruiting | TASK Applied Science | 135 | 2026-09-25 | 2026-09-25 |
| Sorfequiline-based Regimens in Adults With Newly Diagnosed Drug-sensitive Pulmonary TB sorfequiline, Pretomanid, Linezolid - Tuberculosis, Pulmonary | Phase 2 | Recruiting | Global Alliance for TB Drug Development | 100 | 2026-07-09 | 2026-08-19 |
| Bactericidal Activity and Safety of Nicotinamide in Combination With Bedaquiline, Pretomanid, and Linezolid in Drug-susceptible Pulmonary Tuberculosis Bedaquiline, pretomanid, linezolid, Nicotinamide (NAM) - Drug Susceptible Pulmonary Tuberculosis | Phase 2 | Suspended | Gates Medical Research Institute | 165 | 2026-04-17 | 2026-08-10 |
| Bactericidal Activity of TBD09 in Combination With Other Drugs in Pulmonary Tuberculosis Bedaquiline, pretomanid and TBD09, Bedaquiline, pretomanid and linezolid - Drug Susceptible Pulmonary Tuberculosis | Phase 2 | Recruiting | Gates Medical Research Institute | 150 | 2026-04-14 | 2026-07-30 |
| Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis Bedaquiline, Linezolid, Pretomanid - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant | Phase 2 / Phase 3 | Recruiting | University of California, San Francisco | 400 | 2025-10-03 | 2026-09-02 |
| Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis Isoniazid, Rifampicin, Pyrazinamide - Pulmonary Tuberculosis | Phase 2 | Suspended | National Institute of Allergy and Infectious Diseases (NIAID) | 341 | 2025-03-11 | 2026-11-02 |
| Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB Ganfeborole, BTZ-043, Bedaquiline (B) - Pulmonary Tuberculosis | Phase 2 | Recruiting | University College, London | 2500 | 2024-01-09 | 2026-10-15 |
| Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis sorfequiline, Pretomanid, Linezolid - Pulmonary TB, Pulmonary Tuberculosis | Phase 2 | Active not recruiting | Global Alliance for TB Drug Development | 309 | 2023-10-31 | 2026-06-24 |
| A Pan-TB Regimen Targeting Host and Microbe Sutezolid, N-acetyl cysteine, Pretomanid - Tuberculosis | Phase 2 / Phase 3 | Active not recruiting | The Aurum Institute NPC | 352 | 2023-07-28 | 2025-05-28 |
| Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS), Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS), Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE) - Pulmonary Tuberculosis | Phase 2 | Terminated | Gates Medical Research Institute | 93 | 2023-07-26 | 2026-05-20 |
| PanACEA - STEP2C -01 BTZ-043, Rifampicin, Isoniazid - Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis | Phase 2 | Recruiting | Michael Hoelscher | 390 | 2023-04-14 | 2025-10-07 |
| Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis GSK3036656, Bedaquiline, Delamanid - Tuberculosis | Phase 2 | Completed | GlaxoSmithKline | 127 | 2022-07-26 | 2026-06-17 |
| A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Pretomanid, Bedaquiline, moxifloxacin - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant | Phase 2 | Completed | Global Alliance for TB Drug Development | 26 | 2021-09-16 | 2025-01-17 |
| Economic Evaluation of New MDR TB Regimens Bedaquiline, Pretomanid, Moxifloxacin - Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis | Phase 2 / Phase 3 | Completed | Medecins Sans Frontieres, Netherlands | 73 | 2020-10-20 | 2024-04-22 |
| PRACTECAL-PKPD Sub Study Bedaquiline, Pretomanid, Moxifloxacin - Multi-drug Resistant Tuberculosis, Extensively Drug-Resistant Tuberculosis | Phase 2 / Phase 3 | Unknown | Medecins Sans Frontieres, Netherlands | 240 | 2019-08-06 | 2021-05-14 |
| Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients Pretomanid, Bedaquiline, Moxifloxacin - Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant | Phase 2 / Phase 3 | Completed | Global Alliance for TB Drug Development | 455 | 2018-07-30 | 2026-08-27 |
| Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s) Bedaquiline, Pretomanid, Moxifloxacin - Tuberculosis, Multidrug-Resistant, Extensively Drug-Resistant Tuberculosis | Phase 2 / Phase 3 | Completed | Medecins Sans Frontieres, Netherlands | 552 | 2017-01-01 | 2024-05-01 |
| Assessing PA-824 for Tuberculosis (the APT Trial) PA-824, Rifampin, Rifabutin - Pulmonary Tuberculosis | Phase 2 | Completed | Johns Hopkins University | 157 | 2015-04-29 | 2023-07-18 |
| A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis. PA-824, bedaquiline, moxifloxacin - Tuberculosis | Phase 2 | Completed | Global Alliance for TB Drug Development | 240 | 2014-10-23 | 2019-07-26 |
| Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z) TMC207 (J), PA-824 (PA), pyrazinamide (Z) - Pulmonary Tuberculosis | Phase 2 | Completed | Global Alliance for TB Drug Development | 105 | 2012-10-01 | 2016-12-13 |
Showing 20 of 24. Sign in to see all of them.
Tuberculosis, Pulmonary (20) · Tuberculosis (12) · Tuberculosis, Multidrug-Resistant (8) · Extensively Drug-Resistant Tuberculosis (4)
Global Alliance for TB Drug Development (10) · Gates Medical Research Institute (3) · Medecins Sans Frontieres, Netherlands (3) · GlaxoSmithKline (1) · Johns Hopkins University (1) · Michael Hoelscher (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · TASK Applied Science (1) · The Aurum Institute NPC (1) · University College, London (1) · University of California, San Francisco (1)
South Africa (22) · Tanzania (8) · Uganda (7) · Philippines (4) · Belarus (3) · Georgia (3) · Vietnam (3) · Brazil (2) · Malawi (2) · Mozambique (2) · Peru (2) · Uzbekistan (2) · Botswana (1) · Gabon (1) · Haiti (1)
Andreas Diacon, MD (3) · Rodney Dawson, MD (3) · Andreas Diacon (1) · Antonio Lombardi, MD (1) · Bern Nyang'wa, MB BS, MPH (1) · Bern-Thomas Nyang'wa, MD (1) · Fairoez Ryklief, MBBChB (1) · Kelly Dooley, MD, PhD (1) · Kelly E Dooley, MD PhD (1) · Michael Hoelscher, Prof Dr. (1) · Morounfolu Olugbosi (1)
PMID 22430968, PMID 22828481, PMID 25622149, PMID 25795076, PMID 31732485, PMID 33229425, PMID 34489274, PMID 35698158, PMID 36455068, PMID 36546625, PMID 37980911, PMID 38768617, PMID 38842323, PMID 39651910, PMID 40195983, PMID 40817073, PMID 41616265, PMID 41749341, PMID 41917253, PMID 42270675